Jupiter Wealth Management LLC trimmed its holdings in Humana Inc (NYSE:HUM) by 0.5% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 19,258 shares of the insurance provider’s stock after selling 103 shares during the period. Humana makes up about 2.7% of Jupiter Wealth Management LLC’s holdings, making the stock its 15th largest holding. Jupiter Wealth Management LLC’s holdings in Humana were worth $5,430,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of HUM. Whittier Trust Co. purchased a new position in Humana in the second quarter worth approximately $27,000. Next Capital Management LLC purchased a new position in Humana in the second quarter worth approximately $27,000. Destination Wealth Management grew its position in Humana by 130.0% in the first quarter. Destination Wealth Management now owns 115 shares of the insurance provider’s stock worth $31,000 after acquiring an additional 65 shares during the period. Advantage Investment Management LLC grew its position in Humana by 287.1% in the second quarter. Advantage Investment Management LLC now owns 120 shares of the insurance provider’s stock worth $32,000 after acquiring an additional 89 shares during the period. Finally, Coastal Investment Advisors Inc. grew its position in Humana by 1,110.0% in the second quarter. Coastal Investment Advisors Inc. now owns 121 shares of the insurance provider’s stock worth $33,000 after acquiring an additional 111 shares during the period. Institutional investors own 91.33% of the company’s stock.
Several research analysts recently weighed in on HUM shares. Morgan Stanley lowered their price objective on Humana from $331.00 to $315.00 and set an “overweight” rating for the company in a research report on Friday, July 12th. ValuEngine upgraded Humana from a “sell” rating to a “hold” rating in a research note on Friday, July 12th. Citigroup decreased their price target on Humana from $362.00 to $302.00 and set a “buy” rating on the stock in a research note on Thursday, May 2nd. Piper Jaffray Companies upped their price target on Humana from $315.00 to $341.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st. Finally, SunTrust Banks upped their price target on Humana to $340.00 and gave the stock a “hold” rating in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have assigned a buy rating to the stock. Humana currently has a consensus rating of “Buy” and an average price target of $342.26.
Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.05 EPS for the quarter, topping analysts’ consensus estimates of $5.24 by $0.81. Humana had a return on equity of 22.47% and a net margin of 4.13%. The company had revenue of $16.25 billion for the quarter, compared to analysts’ expectations of $15.88 billion. During the same period in the prior year, the firm earned $3.96 earnings per share. The firm’s revenue was up 13.9% compared to the same quarter last year. On average, research analysts forecast that Humana Inc will post 17.63 EPS for the current fiscal year.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading: What is the Coverage Ratio?
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.